TP53 and B-cell chronic lymphocytic leukemia: The incidence and distribution of genetic factors associated with early disease progression such as TP53 disruptions (11.5%, n = 182) and unmutated IGHV mutational status (41.9%, n = 227) was similar to recently reported asymptomatic Binet A stage CLL patients within the CLL12 trial [30].